ClinicalTrials.gg
CompletedNCT00987610G-FORCEUpdated May 4, 2015

Guidewire for Chronic Total Occlusion

A Phase 4 interventional study of Percutaneous coronary intervention (PCI) in Coronary Occlusion, sponsored by Tokai University. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-05-04.

Sponsored by Tokai University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Under the circumstances that appropriate first-choice guidewires for percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) have yet to be established, the objective of this study is to determine appropriate first-choice guidewires. G-FORCE study is a prospective multicenter randomized study between normal (distal tip size 0.014 inch) and slender (distal tip size 0.010 inch or less) guidewires. Primary end point is lesion penetration rate of the first choice guidewire.

Read the detailed description

Background. Although the success rate of PCI for CTO is yet to reach a satisfactory level, prognoses have been improved in successful cases. The greatest challenge is the passage of the guidewire and a variety of new approaches including a parallel wire technique and a retrograde approach have been reported. However, the fundamental question of what type of guidewire is the most appropriate as a first-choice guidewire has not been answered.Tapered guidewires have recently been reported to be useful for CTO lesions. In addition, a multicenter prospective registry indicates the effectiveness of 0.010-inch guidewires (PIKACHU registry, personal communication). Its mechanism is associated with micro-channels ranging from 100 to 300 μm in size in CTO lesions. If 250 μm micro-channels are present in 60% of CTO lesions, a 0.010-inch (equivalent to 250 μm) guidewire theoretically can pass through the lesion at the probability of 60%, and this assumption consists with the findings of the PIKACHU study. This idea also suggests that a 0.014-inch (350 μm) guidewire is unlikely to pass through lesions.

Based on the above, a hypothesis has been formulated that a guidewire with a small tip should be selected as a first-choice guidewire for CTO lesions. In this study, patients will be prospectively randomized to slender guidewires or standard 0.014-inch guidewires to determine appropriate first-choice guidewires.

Objective. To determine appropriate first-choice guidewires.

Design. Prospective multicenter randomized controlled trial

Methods. The first choice guidewire to treat CTO lesion was randomly assigned to normal group (distal tip size 0.014 inch) or slender group (distal tip size 0.010 inch or less). The primary passage must be performed with antegrade approach.

Primary endpoint. Lesion penetration rate of a first-choice guidewire

Power calculation. The PIKACHU registry indicates a 0.010 guidewire passes through a lesion with a success rate of 60%. Assuming the penetration rate of a 0.014 guidewire is 40%, a necessary number of patients would be 260 for a two-sided test with 90% power and significance level of 0.05. Assuming the dropout rate is approximately 10%, the target sample size would be 290 patients.

02

Conditions studied

  • Coronary Occlusion

Browse trials for

Keywords

  • Percutaneous coronary intervention
  • chronic total occlusion
  • guidewire
  • Angioplasty, Transluminal, Percutaneous Coronary
  • Angioplasty
  • Percutaneous Coronary
03

In context

Coronary Occlusion

71 studies on the registry are indexed under Coronary Occlusion; 11 are open to participants now.

This study's enrollment of 260 is above the median of 135 across 45 interventional studies indexed under Coronary Occlusion.

Browse Coronary Occlusion studies →

Lead sponsor

Tokai University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic total occlusion (CTO) lesion in native coronary artery
  • De novo lesion
  • Elective procedure

Exclusion criteria

Exclusion Criteria:

  • No indication of PCI
  • Prior failed lesion
  • Restenotic or in-stent restenotic lesion
  • Vein or arterial grafts
  • Younger than 20 years old
  • Pregnant woman
  • Patients who gave no
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Active comparator
    slender guidewire

    Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less

    Device: Percutaneous coronary intervention (PCI)

  • Active comparator
    normal guidewire

    Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch

    Device: Percutaneous coronary intervention (PCI)

Interventions

  • DevicePercutaneous coronary intervention (PCI)

    PCI for chronic total occlusion is performed using either arm of guidewire

06

What researchers measure

Primary outcomes

  1. Lesion penetration rate of a first-choice guidewire

    Time frame: 30 days

Secondary outcomes

  1. Successful PCI rate

    Time frame: 30 days

  2. Types of guidewires successfully passing through the lesion

    Time frame: 30 days

  3. Major adverse cardio-cerebral events (MACCEs: total death, MI, stroke, and all revascularization procedures)

    Time frame: 30 days

07

Study locations

25 sites
  • Toyohashi Heart Center
    Toyohashi, Aichi, Japan
  • The Jikei University Kashiwa Hospital
    Kashiwa, Chiba, Japan
  • Tokai University
    Isehara, Kanagawa 259-1193, Japan
  • Shonan Kamakura General Hospital
    Kamakura, Kanagawa, Japan
  • Mie Heart Center
    Taki-gun, Mie, Japan
  • Sendai Kousei Hospital
    Sendai, Miyagi, Japan
  • Tohoku Koseinenkin Hospital
    Sendai, Miyagi, Japan
  • Kurashiki Central Hospital
    Kurashiki, Okayama, Japan
  • Kansan Rosai Hospital
    Amagasaki, Japan
  • Aomori Central Hospital
    Aomori, Japan
  • Tsuchiya General Hospital
    Hiroshima, Japan
  • Kokura Kinen hospital
    Kitakyusyu, Japan
  • Takahashi Hospital
    Kobe, Japan
  • Kurune University Hospital
    Kurume, Japan
  • Kyoto University
    Kyoto, Japan
  • Iwate Prefectual Central Hospital
    Morioka, Japan
  • Hyogo College of Medicine
    Nishinomiya, Japan
  • Toho University Omori Medical Hospital Center
    Ota, Japan
  • Hoshi General Hospital
    Sapporo, Japan
  • Sapporo Higashi Tokushukai
    Sapporo, Japan
  • Tokeidai Hospital
    Sapporo, Japan
  • Shizuoka General Hospital
    Shizuoka, Japan
  • Tenri Hospital
    Tenri, Japan
  • Wakayama Medical University
    Wakayama, Japan
  • Yokohama Sakae Kyosai Hospital
    Yokohama, Japan
08

References and documents

Publications

  • Ikari Y, Awata M, Mitsudo K, Akasaka T, Saito S, Ishihara T, Fujii T, Hashimoto H, Terashima M, Ikemoto T, Hibi K, Tazaki J, Nakamura A, Nishikawa H, Sato T, Nakagawa Y. Efficient distal tip size of primary guidewire for antegrade percutaneous coronary intervention in chronic total occlusion: The G-FORCE study. Int J Cardiol. 2017 Jan 15;227:94-99. doi: 10.1016/j.ijcard.2016.11.076. Epub 2016 Nov 9. PubMed 27855293 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2009
First posted
Oct 1, 2009
Start
Oct 2009
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
May 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00987610
Lead sponsor
Tokai University
Responsible party
Yuji Ikari (Professor, Department of Cardiology, Tokai University) — Principal investigator
First posted
Oct 1, 2009
Start date
Oct 2009
Primary completion
Dec 2014
Completion
Dec 2014
Last update
May 4, 2015

Study contacts

Yuji Ikari, MD, PhD
principal investigator · Tokai University
Kazuaki Mitsudo, MD
principal investigator · Kurashiki Central Hospital
Osamu Kato, MD
principal investigator · Toyohashi Heart Center
Shigeru Saito, MD
principal investigator · Shonan Kamakura General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion